Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)
30.50
-0.57 (-1.83%)
At close: May 12, 2026
SHE:301258 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 432.65 | 361.68 | 224.73 | 349.74 | 259.69 | 332.06 |
Trading Asset Securities | 731.79 | 899.07 | 1,123 | 1,070 | 1,161 | 21.61 |
Cash & Short-Term Investments | 1,164 | 1,261 | 1,348 | 1,419 | 1,421 | 353.67 |
Cash Growth | -12.46% | -6.46% | -5.04% | -0.10% | 301.69% | 62.17% |
Accounts Receivable | 129.09 | 96.23 | 101.35 | 62.91 | 97.02 | 87.87 |
Other Receivables | 0.82 | 0.68 | 0.84 | 0.93 | 0.85 | 2.05 |
Receivables | 129.91 | 96.92 | 102.19 | 63.84 | 97.87 | 89.92 |
Inventory | 132.5 | 132.45 | 154.83 | 157.09 | 122.69 | 68.6 |
Other Current Assets | 18.5 | 19.7 | 6.75 | 8.59 | 8.55 | 4.41 |
Total Current Assets | 1,445 | 1,510 | 1,612 | 1,649 | 1,650 | 516.6 |
Property, Plant & Equipment | 537.68 | 524.72 | 398.91 | 387.62 | 416.11 | 421.15 |
Long-Term Investments | 0.2 | 0.2 | 5 | 26.27 | - | - |
Other Intangible Assets | 60.77 | 61.22 | 62.56 | 21.24 | 21.97 | 22.07 |
Long-Term Deferred Tax Assets | 0.33 | 0.33 | 0.07 | 0.01 | 0 | 1.61 |
Long-Term Deferred Charges | 1.69 | 2.01 | 3.28 | 4.55 | - | - |
Other Long-Term Assets | 8.66 | 21.6 | 6.34 | 27.58 | 10.49 | 8.88 |
Total Assets | 2,055 | 2,120 | 2,088 | 2,116 | 2,098 | 970.31 |
Accounts Payable | 124.82 | 173.27 | 118.25 | 84.97 | 114.86 | 124.96 |
Accrued Expenses | 9.87 | 19.9 | 19.16 | 19.48 | 18.47 | 17.85 |
Short-Term Debt | - | - | - | - | - | 18.58 |
Current Portion of Long-Term Debt | 0.71 | 0.71 | - | - | - | - |
Current Portion of Leases | - | - | 0.66 | 0.59 | 0.56 | - |
Current Income Taxes Payable | 2.5 | 1.02 | 4.49 | 1.33 | 3.4 | 3.9 |
Current Unearned Revenue | 0.77 | 2.26 | 1.42 | 2.07 | 6.49 | 6.73 |
Other Current Liabilities | 0.82 | 0.86 | 1.27 | 3.66 | 6.12 | 1.15 |
Total Current Liabilities | 139.49 | 198.01 | 145.25 | 112.1 | 149.91 | 173.17 |
Long-Term Leases | 0.12 | 0.3 | 1.01 | 1.67 | 2.25 | - |
Long-Term Unearned Revenue | 33.4 | 34.13 | 36.99 | 35.27 | 38.38 | 36.42 |
Long-Term Deferred Tax Liabilities | 19.88 | 22.88 | 17.6 | 21.41 | 21.21 | 17.88 |
Total Liabilities | 192.89 | 255.33 | 200.84 | 170.45 | 211.75 | 227.47 |
Common Stock | 91.67 | 91.67 | 91.67 | 91.67 | 91.67 | 68.75 |
Additional Paid-In Capital | 1,144 | 1,144 | 1,144 | 1,144 | 1,144 | 163.42 |
Retained Earnings | 725.02 | 727.79 | 671.75 | 710.32 | 651.31 | 510.67 |
Treasury Stock | -98.51 | -98.51 | -20.14 | - | - | - |
Shareholders' Equity | 1,862 | 1,865 | 1,887 | 1,946 | 1,887 | 742.84 |
Total Liabilities & Equity | 2,055 | 2,120 | 2,088 | 2,116 | 2,098 | 970.31 |
Total Debt | 0.84 | 1.01 | 1.67 | 2.25 | 2.82 | 18.58 |
Net Cash (Debt) | 1,164 | 1,260 | 1,346 | 1,417 | 1,418 | 335.09 |
Net Cash Growth | -12.43% | -6.42% | -5.00% | -0.06% | 323.12% | 53.65% |
Net Cash Per Share | 12.92 | 13.91 | 14.77 | 15.41 | 16.47 | 4.88 |
Filing Date Shares Outstanding | 88.71 | 90.35 | 90.82 | 91.67 | 91.67 | 68.75 |
Total Common Shares Outstanding | 88.71 | 90.35 | 90.82 | 91.67 | 91.67 | 68.75 |
Working Capital | 1,306 | 1,312 | 1,466 | 1,537 | 1,500 | 343.43 |
Book Value Per Share | 20.99 | 20.64 | 20.78 | 21.22 | 20.58 | 10.80 |
Tangible Book Value | 1,801 | 1,803 | 1,824 | 1,924 | 1,865 | 720.76 |
Tangible Book Value Per Share | 20.30 | 19.96 | 20.09 | 20.99 | 20.34 | 10.48 |
Buildings | - | - | 254.18 | 253.42 | 251.56 | 253.49 |
Machinery | - | - | 470.51 | 454.95 | 436.91 | 384.41 |
Construction In Progress | - | - | 38.15 | 1.49 | 0.43 | 12.17 |
Order Backlog | - | - | 81.26 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.